Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/8/2025

Management of Hyperlipidemia

Introduction to Hyperlipidemia Management

  • Hyperlipidemia management involves a combination of lifestyle modifications and pharmacotherapy, with daily physical activity and weight management recommended for patients with hypercholesterolemia 1
  • Dietary therapy should include reduced intake of saturated fats (<7% of total calories), trans fatty acids (<1% of total calories), and cholesterol (<200 mg/d) 1

Alternative Therapies for Statin-Intolerant Patients

  • For patients with high LDL cholesterol and triglycerides who cannot take statins with ezetimibe, the European Heart Journal recommends bile acid sequestrants and/or fibrates as first-line alternative therapies, with caution as they may increase triglycerides, so monitoring is necessary 2
  • Fibrates are particularly effective for patients with high triglycerides, according to the European Heart Journal 2
  • Prescription omega-3 fatty acids at doses of 2-4g/day can be used for triglyceride lowering, as suggested by the European Heart Journal 2
  • Ezetimibe may be considered for patients who do not tolerate statins or bile acid sequestrants, and can reduce LDL-C by approximately 18% as monotherapy 1, 3

PCSK9 Inhibitors for High-Risk Patients

  • The Arteriosclerosis, Thrombosis, and Vascular Biology journal suggests considering PCSK9 inhibitors for high-risk patients with established cardiovascular disease or heterozygous familial hypercholesterolemia, which can reduce LDL-C by 50-60% 4
  • PCSK9 inhibitors can provide substantial LDL-C reduction (typically 50-60%) and may be considered for patients with established cardiovascular disease or heterozygous familial hypercholesterolemia who cannot achieve adequate LDL-C reduction with first-line agents 3, 5

Combination Therapy and Monitoring

  • The European Heart Journal recommends adding prescription omega-3 fatty acids to fibrate therapy for severe hypertriglyceridemia 2
  • The Diabetes Care journal notes that niacin can affect glycemic control at high doses but may be used at modest doses with appropriate adjustment of diabetes therapy, and gemfibrozil has shown benefit in reducing cardiovascular events in diabetic subgroups 6
  • Combination therapy requires vigilance for potential drug interactions and monitoring for adverse effects, and patients on PCSK9 inhibitors should be monitored for adverse effects, with LDL-C levels measured just prior to the next scheduled dose 5
  • It is recommended to check lipid profile 4-6 weeks after initiating therapy to assess response, and monitor liver function tests with fibrate therapy 2

Treatment Approach and Prioritization

  • The approach prioritizes triglyceride-lowering therapy (fibrates, omega-3) before LDL-lowering therapy to reduce pancreatitis risk if triglycerides are severely elevated (>500 mg/dL) 2
  • The American Heart Association/American College of Cardiology Foundation recommends bile acid sequestrants and/or niacin as first-line therapy for patients with hypercholesterolemia who cannot take statins or fenofibrate, with a Level of Evidence: B 1
  • Bile acid sequestrants and/or niacin are recommended as first-line pharmacotherapy for patients with hypercholesterolemia who cannot take statins or fenofibrate, and can reduce LDL-C by approximately 18-25% when used as monotherapy 1

Special Considerations and Referrals

  • Referral to a lipid specialist may be considered for patients with complex lipid disorders or multiple medication intolerances 3
  • The American College of Cardiology recommends avoiding combining gemfibrozil with any remaining statin therapy due to higher risk of myopathy compared to fenofibrate 5
  • Omega-3 fatty acids (1 g/day) may be reasonable for cardiovascular disease risk reduction, according to the American Heart Association 1
  • Bempedoic acid may be considered, especially in combination with ezetimibe, for statin-intolerant patients 5